News ArticleDeepak Nitrite Limited Approves Unaudited Financial Results for Q2 and H1 September 2026
Board of Directors endorses standalone and consolidated results reviewed by Deloitte on 29th October 2026
Deepak Nitrite Limited announced its unaudited standalone and consolidated financial results for the quarter and half year ended 30th September 2026, reviewed by Deloitte Haskins & Sells LLP, with report approved by the Board on 29th October 2026.
Deepak Nitrite Limited
Financial Results
Deepak Nitrite Limited's Board approved the unaudited standalone and consolidated financial results for the quarter and half year ended 30th September 2026, with a limited review conducted by Deloitte Haskins & Sells LLP.
The results cover both standalone and consolidated financial statements for the specified periods, reflecting the company's financial position and performance.
The review was carried out by the company's statutory auditors, Deloitte Haskins & Sells LLP, ensuring compliance with SEBI Listing Regulations.
The Board meeting was held on 29th October 2026, starting at 2:00 p.m. and concluding at 4:00 p.m., during which these financial results were approved.
The announcement fulfills the regulatory requirements stipulated under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Highlights
- Unaudited standalone and consolidated financial results approved for Q2 and H1 ending 30th September 2026.
- Limited review by Deloitte Haskins & Sells LLP as statutory auditors.
- Board meeting held on 29th October 2026 from 2:00 p.m. to 4:00 p.m.
- Filing complies with SEBI Listing Regulation 33 requirements.
Key Data Snapshot
What happened
- Deepak Nitrite Limited's Board approved unaudited standalone and consolidated financial results for Q2 and H1 ending 30th September 2026.
- A limited review report was issued by Deloitte Haskins & Sells LLP, the company's statutory auditors.
Regulatory and governance context
- The financial results are in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The approval was taken at the Board meeting conducted on 29th October 2026, from 2:00 p.m. to 4:00 p.m.
Highlights
- Unaudited standalone and consolidated financial results approved for Q2 and H1 ending 30th September 2026.
- Limited review by Deloitte Haskins & Sells LLP as statutory auditors.
- Board meeting held on 29th October 2026 from 2:00 p.m. to 4:00 p.m.
- Filing complies with SEBI Listing Regulation 33 requirements.
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Regulation 33
Source Information
More News on Financial Results
View allLatest corporate announcements and market updates in Financial Results.
Indegene Limited Announces Unaudited Consolidated and Standalone Results for Q2 and H1 Ending September 30, 2026
Indegene Limited approved its unaudited consolidated and standalone financial results for the second quarter and half year ended September 30, 2026, alongside approving allotments under RSU and ESOP schemes and key personnel resignations during its board meeting on October 29, 2026.
Read Full Story
Alivus Life Sciences Posts ₹3,568 Million Net Profit in First Half of FY2026, Q2 Net Profit at ₹1,967 Million
Alivus Life Sciences Limited has reported its unaudited financial results for the second quarter and half year ended September 30, 2026, posting a net profit of ₹1,967 million for the quarter and ₹3,568 million for the half year, supported by revenue growth.
Read Full Story
Timken India Limited Achieves Rs 2,311.94 Million Net Profit for First Half of FY 2026-27
Timken India Limited reported a net profit after tax of Rs 2,311.94 million for the half year ended September 30, 2026, with revenue from operations totaling Rs 18,983.82 million, as per its unaudited standalone financial results approved by the Board on October 29, 2026.
Read Full Story
